Status:
RECRUITING
HER2 Status in Esophagogastric Adenocarcinoma and Its Associations With Patient's Clinicopathological Outcomes
Lead Sponsor:
St. James's Hospital, Ireland
Conditions:
Esophagus Cancer
Gastric Cancer
Eligibility:
All Genders
Brief Summary
Targeted therapies offer promise to improve oncologic outcomes in esophagogastric adenocarcinoma (EGA). The landmark 'Trastuzumab for gastric cancer (ToGA)' trial established the therapeutic value of ...
Eligibility Criteria
Inclusion
- Patients with newly diagnosed EGA from 2000 to April 2024 across all stages of disease
- Primary tumour HER2 status tested as routine in all patients with EGA
- Patients aged 18 years or over
Exclusion
- \- Patients with esophageal squamous cell carcinoma
Key Trial Info
Start Date :
August 20 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
August 31 2025
Estimated Enrollment :
2188 Patients enrolled
Trial Details
Trial ID
NCT06550063
Start Date
August 20 2024
End Date
August 31 2025
Last Update
August 13 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Trinity St James Cancer Institute
Dublin, Leinster, Ireland, D08 NHY1